Analysis of efficacy and cost-effectiveness of high-dose arabinoside versus daunorubicin chemotherapy in older adult patients with acute myeloid leukemia by cytogenetic risk profile: Retrospective review from China

International Journal of Hematology

Volumn 93, Issue 4, 2011, Pages 474-481

  Huang, Bin Tao ^a   Wang, Yu ^a   Du, Qing Feng ^a   Yang, Jun ^a   Yu, Jessica ^b   Zeng, Qing Chun ^c   Xu, Na ^a   Zhang, Jin Fang ^a   Xu, Lu Lu ^a   Luo, Xu Jing ^a   Wei, Yong Qiang ^a   Liu, Xiao Li ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF COLORADO   (United States)

^c GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; Cost effectiveness; Cytogenetic risk; Daunorubicin; High dose arabinoside; Treatment

Indexed keywords

ARABINOSIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HEMOGLOBIN; HOMOHARRINGTONINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CHINA; CLINICAL ASSESSMENT; CONTINUOUS INFUSION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOGENETICS; CYTOGENETICS AND SOMATIC CELL GENETICS; DRUG EFFICACY; DRUG MEGADOSE; ERYTHROCYTE CONCENTRATE; EVENT FREE SURVIVAL; FEMALE; FLUOROIMMUNOASSAY; FOLLOW UP; HOSPITAL COST; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; METAPHASE CHROMOSOME; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; RETROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TREATMENT DURATION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; COST-BENEFIT ANALYSIS; CYTARABINE; CYTOGENETIC ANALYSIS; DAUNORUBICIN; FEMALE; HEALTH CARE COSTS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED;

EID: 79955939420     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-011-0804-0     Document Type: Article

References (28)

1. Stone RM, O'Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematol Am Soc Hematol Educ Program. 2004;98-117.
2. Burnett AK, Wheatley K, Goldstone AH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol. 2002;118:385-400. (Pubitemid 34994639)
3. Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood. 2003;102:1232-40. (Pubitemid 36988027)
4. Schlenk RF, Benner A, Hartmann F, del Valle F, Weber C, Pralle H, et al. Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia. 2003;17:1521-8. (Pubitemid 36986953)
5. Fagundes EM, Rocha V, Glória AB, Clementino NC, Quintão JS, Guimarães JP, et al. De novo acute myeloid leukemia in adults younger than 60 years of age: socioeconomic aspects and treatment results in a Brazilian university center. Leuk Lymphoma. 2006;47:1557-64. (Pubitemid 44364021)
6. Böhm A, Piribauer M, Wimazal F, Geissler K, Gisslinger H, Knöbl P, et al. High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience. Leuk Res. 2005;29:609-15. (Pubitemid 40603559)
7. Rowe JM. Optimal induction and post-remission therapy for AML in first remission. Hematol Am Soc Hematol Educ Program. 2009;396-405.
8. Bieker R, Lerchenmüller C, Wehmeyer J, Serve HL, Mesters RM, Büchner T, et al. Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia. Oncol Rep. 2003;10:915-20.
9. Löwenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol. 1998;16:872-81. (Pubitemid 28115455)
10. Link H, Frauer HM, Ostendorf P, Waller HD. Therapy for acute myeloid leukemia in 119 adults: a comparison of two treatment protocols. Blut. 1985;51:49-56.
11. Nowrousian MR, Kubaschinski G, Hossfeld DK, Schaefer UW, Schmidt CG. Results of treatment of acute myeloid leukemia in adults. Onkologie. 1983;6:184-6. (Pubitemid 14226656)
12. Hollard D, Sotto JJ, Berthier R, Leger J, Michallet M. High rate of long-term survivals in AML treated by chemotherapy and androgenotherapy: a pilot study. Cancer. 1980;45:1540-8. (Pubitemid 10144997)
13. Rogers BB. Advances in the management of acute myeloid leukemia in older adult patients. Oncol Nurs Forum. 2010;37:168-79.
14. Chang C, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood. 2007;110:1379-87. (Pubitemid 47281440)
15. Paciucci PA, Cuttner J, Gottlieb A, Davis RB, Martelo O, Holland JF. Sequential mitoxantrone, daunorubicin, and cytosine arabinoside for patients with newly diagnosed acute myelocytic leukemia. Am J Hematol. 1997;56:214-8. (Pubitemid 127471671)
16. Stone RM. The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin. 2002;52:363-71. (Pubitemid 35446607)
17. Pashko S, Jacobs J, Santorsa J. The cost-effectiveness of idarubicin/cytosine arabinoside versus daunorubicin/cytosine arabinoside in the treatment of adults with acute myeloid leukemia. Clin Ther. 1991;13:353-60.
18. Yu YB, Gau JP, You JY, Chern HH, Chau WK, Tzeng CH, et al. Cost-effectiveness of postremission intensive therapy in patients with acute leukemia. Ann Oncol. 2007;18:529-34.
19. Appelbaum FR, Baer MR, Carabasi MH, Coutre SE, Erba HP, Estey E, et al. NCCN practice guidelines for acute myelogenous leukemia. Oncology. 2000;14:53-61.
20. van den Heuvel-Eibrink MM, van der Holt B, Burnett AK, Knauf WU, Fey MF, Verhoef GE, et al. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann Hematol. 2007;86:329-37.
21. Bassan R, Raimondi R, Lerede T, D'emilio A, Buelli M, Borleri G, et al. Outcome assessment of age group-specific (±50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia. Haematologica. 1998;83:627-35.
22. Xu W, Tang Y, Song H, Shi S, Yang S. Retrospective study on elimination delay of methotrexate in high-dose therapy of childhood acute lymphoblastic leukemia in China. J Pediatr Hematol Oncol. 2007;29:688-93. (Pubitemid 47549180)
23. Redaelli A, Botteman MF, Stephens JM. Economic burden of acute myeloid leukemia: a literature review. Cancer Treat Rev. 2004;30:237-47. (Pubitemid 38477269)
24. Marie JP, Wdowik T, Bisserbe S, Zittoun R. Cost of complete remission induction in acute myeloblastic leukemia: evaluation of the cost-effectiveness of a new drug. Leukemia. 1992;6:720-2.
25. Zheng S, Song M, Wu L, Yang S, Shen J, Lu X, et al. China: public health genomics. Public Health Genomics. 2010;13:269-75.
26. Clavio M, Quintino S, Masoudi B, Carrara S, Cerri R, Pierri I, Canepa L, et al. Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens. J Exp Clin Cancer Res. 2001;20:165-73. (Pubitemid 32641056)
27. Mandelli F, Vignetti M, Suciu S, Stasi R, Petti MC, Meloni G, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol. 2009;27:5397-403.
28. Qian SX, Li JY, Wu HX. Standard-dose of idarubicin in combination with continuous infusion of cytarabine as induction therapy in patients with acute myeloid leukaemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009;17:209-13.